DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
Ovarian cancer (OC) is the seventh most common type of cancer in women worldwide. Treatment for OC usually involves a combination of surgery and chemotherapy with carboplatin and paclitaxel. Platinum-based agents exert their cytotoxic action through development of DNA damage, including the formation...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/1/82 |
| _version_ | 1797495604073463808 |
|---|---|
| author | Dimitra T. Stefanou Vassilis L. Souliotis Roubini Zakopoulou Michalis Liontos Aristotelis Bamias |
| author_facet | Dimitra T. Stefanou Vassilis L. Souliotis Roubini Zakopoulou Michalis Liontos Aristotelis Bamias |
| author_sort | Dimitra T. Stefanou |
| collection | DOAJ |
| description | Ovarian cancer (OC) is the seventh most common type of cancer in women worldwide. Treatment for OC usually involves a combination of surgery and chemotherapy with carboplatin and paclitaxel. Platinum-based agents exert their cytotoxic action through development of DNA damage, including the formation of intra- and inter-strand cross-links, as well as single-nucleotide damage of guanine. Although these agents are highly efficient, intrinsic and acquired resistance during treatment are relatively common and remain a major challenge for platinum-based therapy. There is strong evidence to show that the functionality of various DNA repair pathways significantly impacts tumor response to treatment. Various DNA repair molecular components were found deregulated in ovarian cancer, including molecules involved in homologous recombination repair (HRR), nucleotide excision repair (NER), mismatch repair (MMR), non-homologous end-joining (NHEJ), and base excision repair (BER), which can be possibly exploited as novel therapeutic targets and sensitive/effective biomarkers. This review attempts to summarize published data on this subject and thus help in the design of new mechanistic studies to better understand the involvement of the DNA repair in the platinum drugs resistance, as well as to suggest new therapeutic perspectives and potential targets. |
| first_indexed | 2024-03-10T01:52:02Z |
| format | Article |
| id | doaj.art-775daf14f30c4e1cb70cd7d4a96d0048 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T01:52:02Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-775daf14f30c4e1cb70cd7d4a96d00482023-11-23T13:03:29ZengMDPI AGBiomedicines2227-90592021-12-011018210.3390/biomedicines10010082DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?Dimitra T. Stefanou0Vassilis L. Souliotis1Roubini Zakopoulou2Michalis Liontos3Aristotelis Bamias4First Department of Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, GreeceInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, GreeceDepartment of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, GreeceOvarian cancer (OC) is the seventh most common type of cancer in women worldwide. Treatment for OC usually involves a combination of surgery and chemotherapy with carboplatin and paclitaxel. Platinum-based agents exert their cytotoxic action through development of DNA damage, including the formation of intra- and inter-strand cross-links, as well as single-nucleotide damage of guanine. Although these agents are highly efficient, intrinsic and acquired resistance during treatment are relatively common and remain a major challenge for platinum-based therapy. There is strong evidence to show that the functionality of various DNA repair pathways significantly impacts tumor response to treatment. Various DNA repair molecular components were found deregulated in ovarian cancer, including molecules involved in homologous recombination repair (HRR), nucleotide excision repair (NER), mismatch repair (MMR), non-homologous end-joining (NHEJ), and base excision repair (BER), which can be possibly exploited as novel therapeutic targets and sensitive/effective biomarkers. This review attempts to summarize published data on this subject and thus help in the design of new mechanistic studies to better understand the involvement of the DNA repair in the platinum drugs resistance, as well as to suggest new therapeutic perspectives and potential targets.https://www.mdpi.com/2227-9059/10/1/82ovarian cancerDNA repairplatinum drugseffective biomarkerstherapeutic targets |
| spellingShingle | Dimitra T. Stefanou Vassilis L. Souliotis Roubini Zakopoulou Michalis Liontos Aristotelis Bamias DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? Biomedicines ovarian cancer DNA repair platinum drugs effective biomarkers therapeutic targets |
| title | DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? |
| title_full | DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? |
| title_fullStr | DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? |
| title_full_unstemmed | DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? |
| title_short | DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer? |
| title_sort | dna damage repair predictor of platinum efficacy in ovarian cancer |
| topic | ovarian cancer DNA repair platinum drugs effective biomarkers therapeutic targets |
| url | https://www.mdpi.com/2227-9059/10/1/82 |
| work_keys_str_mv | AT dimitratstefanou dnadamagerepairpredictorofplatinumefficacyinovariancancer AT vassilislsouliotis dnadamagerepairpredictorofplatinumefficacyinovariancancer AT roubinizakopoulou dnadamagerepairpredictorofplatinumefficacyinovariancancer AT michalisliontos dnadamagerepairpredictorofplatinumefficacyinovariancancer AT aristotelisbamias dnadamagerepairpredictorofplatinumefficacyinovariancancer |